NCT03872349

Effects of Monounsaturated Fatty Acids on Intestinal Lipid Metabolism in Insulin Resistant Subjects (MUFA )

Completed NA Last updated 9 October 2024

What this trial tests

NA trial testing Monounsaturated fatty acids diet in Metabolic Syndrome in 18 participants. Completed in 4 October 2024.

Timeline

9 February 2020

Primary endpoint
19 February 2024

4 October 2024

Quick facts

Lead sponsor	Laval University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	prevention
Enrollment	18
Start date	9 February 2020
Primary completion	19 February 2024
Estimated completion	4 October 2024
Sites	1 location across Canada

Drugs / interventions tested

• Monounsaturated fatty acids diet
• Saturated fatty acids diet

Conditions studied

• Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Laval University

Who can join

Adults 18 to 60, any sex, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overaccumulation of apolipoprotein (apo)B-48-containing lipoproteins of intestinal origin observed in patients with insulin-resistance is now thought to be attributable to both elevated intestinal production and reduced clearance of these lipoproteins. Substantial evidence exists indicating that elevated plasma levels of these lipoproteins are associated with increased cardiovascular disease (CVD) risk. Therefore, reduction of atherogenic plasma triglyceride-rich lipoproteins à (TRL) levels of intestinal origin appears to be crucial to improve CVD risk associated with insulin-resistance. In this regard, there is some evidence that the clinical recommendation to replace dietary saturated fatty acids (SFAs) by monounsaturated fatty acids (MUFAs) reduces CVD risk in the general population. Although the beneficial impact of PUFAs on CVD risk has been related primarily to favorable changes in plasma LDL-cholesterol levels, recent data suggest that chronic MUFA consumption may also exert beneficial effects on CVD risk by reducing postprandial lipemia. The impact of substituting SFAs by MUFAs on postprandial lipid response may be of even greater significance in dyslipidemic patients with insulin-resistance among whom intestinal TRLs represent a large proportion of the atherogenic lipoproteins. The general objective of the proposed research is to investigate how dietary MUFAs in place of SFAs modify intestinal lipoprotein metabolism in men and women with dyslipidemia associated with insulin-resistance. The investigators hypothesize that the intestinal secretion of apoB-48-containing lipoproteins will be lower following a diet rich in MUFAs than after consuming a diet rich in SFAs. The investigators also hypothesize that substitution of SFAs by MUFAs will be associated with significant alterations in expression of key genes and proteins involved in intestinal lipoprotein metabolism.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Substitution of dietary monounsaturated fatty acids from olive oil for saturated fatty acids from lard increases low-density lipoprotein apolipoprotein B-100 fractional catabolic rate in subjects with dyslipidemia associated with insulin resistance: a randomized controlled trial.
   Desjardins LC, Brière F, Tremblay AJ, Rancourt-Bouchard M, et al · · 2024 · cited 4× · PMID 38518848 · DOI 10.1016/j.ajcnut.2024.03.015